---
title: "Tianda Pharmaceuticals Narrows Comprehensive Loss Despite Higher Interim Revenue"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295440586.md"
description: "Tianda Pharmaceuticals reported interim revenue of HK$164.2 million for the six months ended June 30, 2026, up from HK$136.6 million a year earlier. Despite higher sales, the company recorded a net loss of HK$32.2 million and a total comprehensive loss of HK$15.2 million. The narrowing comprehensive loss was aided by exchange gains, though profitability remains pressured by increased operating expenses and finance costs."
datetime: "2026-08-10T15:08:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295440586.md)
  - [en](https://longbridge.com/en/news/295440586.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295440586.md)
generator: "portal-rs"
---

# Tianda Pharmaceuticals Narrows Comprehensive Loss Despite Higher Interim Revenue

The latest update is out from Tianda Pharmaceuticals Ltd. ( (HK:0455) ).

Tianda Pharmaceuticals reported interim revenue of HK$164.2 million for the six months ended 30 June 2026, up from HK$136.6 million a year earlier, driven by higher sales despite increased cost of sales and operating expenses. The company’s gross profit rose to HK$66.1 million, but the group still recorded a net loss of HK$32.2 million and a total comprehensive loss of HK$15.2 million, reflecting ongoing pressures on profitability even as top-line performance improved.

Selling, distribution and administrative expenses continued to weigh on the bottom line, alongside finance costs, though research and development spending declined versus the prior period. Currency movements provided some offset through exchange gains in other comprehensive income, slightly narrowing the overall comprehensive loss and highlighting the group’s exposure to foreign exchange swings in its geographically diversified operations.

**More about Tianda Pharmaceuticals Ltd.**

Tianda Pharmaceuticals Limited is a Hong Kong-listed pharmaceutical company engaged in the development, manufacture and sale of pharmaceutical products. The group focuses on healthcare solutions and operates through various subsidiaries, with a presence in mainland China and international markets.

**Average Trading Volume:** 142,193

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$221.5M

### Related Stocks

- [00455.HK](https://longbridge.com/en/quote/00455.HK.md)

## Related News & Research

- [Tianda Pharma FY26 interim net loss narrows to HK$32.25 million; revenue rises 20.2% to HK$164.22 million](https://longbridge.com/en/news/295423729.md)
- [Lenovo Group: Record sales and adjusted profit growth were offset in reported results by warrant revaluation losses](https://longbridge.com/en/news/306059225.md)
- [Kuaishou Technology: Q3 loss and weaker revenue meet intensifying competition and costly AI investment](https://longbridge.com/en/news/306088382.md)
- [How did Coinbase stop deepfake Elon Musk’s promise to double your crypto?](https://longbridge.com/en/news/306049317.md)
- [Revenue Guidance Could Be A Game Changer For Hesai Group Stock (HSAI)](https://longbridge.com/en/news/305993381.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**